Goldman Sachs Adjusts Price Target on Zimmer Biomet to $86 From $89, Maintains Sell Rating

robot
Abstract generation in progress

Goldman Sachs has adjusted its price target for Zimmer Biomet (ZBH) to $86 from $89, while maintaining a Sell rating on the stock. This report is part of a series of analyst adjustments for Zimmer Biomet on the same day, reflecting varied opinions on the company’s outlook. The medical device maker specializes in orthopedic reconstruction implants and traumatology products.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments